µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y412 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׸»¶ó¸®¾ÆÁ¦ ¹× ±âŸ Ç÷¾×³» ¿øÃæ·ù¿¡ ÀÛ¿ëÇÏ´Â ¾à¹° Antimalarials and drugs acting on other blood protozoa causing adverse effects in therapeutic use
Y413 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç׿øÃæÁ¦ Other antiprotozoal drugs causing adverse effects in therapeutic use
Y414 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸ÃæÁ¦ Anthelminthics causing adverse effects in therapeutic use
Y415 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×¹ÙÀÌ·¯½ºÁ¦ Antiviral drugs causing adverse effects in therapeutic use
Y418 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¸í½ÃµÈ Àü½Å Ç×°¨¿°Á¦ ¹× Ç×±â»ýÃæÁ¦ Other specified systemic anti-infectives and antiparasitics causing adverse effects in therapeutic use
Y418 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÇÏÀ̵å·Ï½ÃÄû³ë¸° À¯µµÃ¼ Hydroxyquinoline derivatives causing adverse effects in therapeutic use
Y419 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ Àü½Å Ç×°¨¿°Á¦ ¹× Ç×±â»ýÃæÁ¦ Systemic anti-infective and antiparasitic, unspecified causing adverse effects in therapeutic use
Y42 Ä¡·á½Ã ºÎÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº È£¸£¸ó ¹× ±×µéÀÇ ÇÕ¼º ´ë¿ëǰ ¹× ´ëÇ×Á¦(±æÇ×Á¦) Hormones and their synthetic substitutes and antagonists,NEC causing adverse effects in therapeutic use
Y420 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±Û·çÄÚÄÝÆ¼ÄÚÀÌµå ¹× ÇÕ¼º´ëÄ¡¹° Glucocorticoids and synthetic analogues causing adverse effects in therapeutic use
Y421 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °©»ó¼± È£¸£¸ó ¹× ´ëÄ¡¹° Thyroid hormones and substitutes causing adverse effects in therapeutic use
Y422 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×°©»ó¼±Á¦ Antithyroid drugs causing adverse effects in therapeutic use
Y423 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Àν¶¸° ¹× °æ±¸ÀúÇ÷´ç[Ç×´ç´¢º´]Á¦ Insulin and oral hypoglycemic [antidiabetic] drugs causing adverse effects in therapeutic use
Y424 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °æ±¸ÇÇÀÓÁ¦ Oral contraceptives causing adverse effects in therapeutic use
Y424 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Ù¼ººÐ ¹× ´ÜÀϼººÐ Á¦Á¦ Multiple-and single-ingredient preparations causing adverse effects in therapeutic use
Y425 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¿¡½ºÆ®·Î°Õ ¹× ÇÁ·Î°Ô½ºÅ×·Ð Other estrogens and progestogens causing adverse effects in therapeutic use
Y425 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â È¥ÇÕ¹° ¹× ´ëÄ¡¹° Mixtures and substitutes causing adverse effects in therapeutic use
Y426 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº Ç×°í³ªµµÆ®·ÎÇÉÁ¦, Ç׿¡½ºÆ®·ÎÁ¨Á¦, Ç׾ȵå·ÎÁ¨Á¦ Antigonadotrophins, antiestrogens, antiandrogens, NEC causing adverse effects in therapeutic use
Y426 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ÿ¸ñ½ÃÆæ Tamoxifen causing adverse effects in therapeutic use
Y427 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Èµå·ÎÁ¨ ¹× ÇÕ¼º´ë»ç µ¿Á¾Ã¼ Androgens and anabolic congeners causing adverse effects in therapeutic use
Y428 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ È£¸£¸ó ¹× ÇÕ¼º ´ëÄ¡¹° Other and unspecified hormones and their synthetic substitutes causing adverse effects in therapeutic use
1901  1902  1903  1904  1905  1906  1907  1908  [1909] 1910